Invirsa: Funding, Investors & Team (Sep 2026)

Invirsa is working on the development of a small molecule known as INV-102. This molecule has the ability to enhance the healing of wounds by promoting both DNA repair and the innate immune response to infections and injuries. As a result, it leads to a decrease in inflammation and viral replication. INV-102 has shown remarkable effectiveness in animal studies related to ocular sulfur mustard gas injury. This gas is a dangerous chemical weapon, and INV-102 is the first drug to display potential in preventing its long-term consequences. Currently, there is no FDA approved treatment for this type of injury. In September 2020, Invirsa received a $29.6 million BARDA award, with $14.4 million given upfront and an additional $15.2 million based on achieving certain milestones. This funding will support the clinical development of INV-102 for the treatment of ocular sulfur mustard gas injury and other eye injuries caused by DNA damage. The award also covers the development of the drug until Phase 3 clinical trials. Initially, Invirsa plans to focus on using INV-102 for the treatment of infectious keratoconjunctivitis, a condition where there is currently no available treatment for the viral form that accounts for 80% of all cases. Animal studies have shown that INV-102 is highly effective in treating infectious conjunctivitis.

Invirsa has raised $7.7M across 1 round on record. The most recent is a Series B of $7.7M announced in Jun 2023.

Invirsa's most recent funding round on record is a Series B of $7.7M, announced in Jun 2023.

FundedIQ lists Frank Scardena (Founder) at Invirsa.

Invirsa is based in Columbus, Ohio, United States.

Invirsa is in the 11-50 employee band.

Invirsa's latest round of $7.7M is in line with the $8.0M median round size for Biotechnology companies on FundedIQ across 4,179 tracked companies over the last two years.